Every Form 4 that Tonix Pharmaceut (TNXP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TNXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNXP filings page.
Tonix Pharmaceuticals Holding Corp. (TNXP) director and Chief Executive Officer Seth Lederman reported buying common stock on August 27, 2026. An IRA account associated with him purchased 2,000 shares of common stock at $13.79 per share in an open-market or private transaction, held as indirect ownership. After this purchase, the IRA account held 11,005 shares. Separate from this, he also reported 20,001 shares held directly and 1 share held indirectly through Lederman & Co., for which he may be deemed a control person.
Tonix Pharmaceuticals Holding Corp. (TNXP) director Richard H. Bagger reported purchasing 1,000 shares of the company’s common stock on August 20, 2026. The shares were bought at a price of $12.60 per share, and he now holds 1,000 shares of Tonix common stock directly.
Tonix Pharmaceuticals Holding Corp. Chief Financial Officer Bradley Saenger reported a routine share acquisition through an employee stock plan. He obtained 1,453 shares of common stock at a price of $10.914 per share via the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan.
Following this transaction, Saenger directly holds 2,154 shares of Tonix common stock. The transaction is coded as “J” (other acquisition or disposition), reflecting a compensation-related, plan-based purchase rather than an open-market trade, so it carries limited signaling value about his view of the stock.
Tonix Pharmaceuticals Holding Corp. director Carolyn E. Taylor reported an open-market purchase of common stock. She bought 1,415 shares of Tonix common stock at an average price of $10.55 per share. After this transaction, she directly owns 1,833 shares of Tonix common stock.
Tonix Pharmaceuticals Holding Corp. director Richard Newcomb Stillwell reported an open-market purchase of 5,000 common shares. The shares were bought on June 8, 2026 at a weighted average price of $11.65 per share, with individual trade prices ranging from $11.63 to $11.65. Following this transaction, Stillwell directly holds 5,000 Tonix common shares.
Tonix Pharmaceuticals Holding Corp. Chief Executive Officer Seth Lederman reported an open-market purchase of common stock. On June 9, 2026, he bought 5,000 shares at a weighted average price of $11.79 per share in a series of trades priced between $11.735 and $11.883.
Following this purchase, Lederman directly owns 9,005 common shares. He also has indirect ownership of 1 share through Lederman & Co. and 20,001 shares through an IRA account, where he may be deemed a control person of the Lederman & Co. entity.
Tonix Pharmaceuticals Holding Corp. director Richard Newcomb Stillwell received a stock option grant covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share and expire on May 12, 2036. They were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. After this compensation award, Stillwell holds 22,700 derivative securities linked to common stock directly, with no open-market purchase or sale reported in this filing.
Tonix Pharmaceuticals Holding Corp. director Adeoye Y Olukotun reported receiving a stock option grant covering 22,700 shares of common stock. The option has an exercise price of $13.28 per share and expires on May 12, 2036. It was granted under the company’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Following this grant, Olukotun holds stock options for 22,700 underlying shares directly.
Tonix Pharmaceuticals Holding Corp. director Margaret Smith Bell received a grant of stock options as part of equity compensation. She was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share. The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, she holds derivative rights to 22,700 shares through these options, which expire in 2036.
Tonix Pharmaceuticals Holding Corp. director Hunter James Randolph Jr reported receiving a grant of stock options as part of his compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share, with no cash paid at grant.
The options were granted under the company’s 2026 Stock Incentive Plan and vest on the earlier of one year from the grant date or the company’s 2027 Annual Meeting of Stockholders. Following this grant, Randolph holds options for 22,700 underlying shares directly.
Tonix Pharmaceuticals Holding Corp. director James Treco received a grant of stock options as part of equity compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share, expiring in 2036.
The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the May 12, 2026 grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, Treco holds options for 22,700 shares directly.
Tonix Pharmaceuticals Holding Corp. director David L. Grange received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share, vest on the earlier of one year from grant or the 2027 annual stockholders meeting, and expire in 2036.
Tonix Pharmaceuticals Holding Corp. director Richard H. Bagger received a grant of stock options as part of his compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share. These options were granted under the company’s 2026 Stock Incentive Plan and vest on the earlier of one year after the grant date or the 2027 Annual Meeting of Stockholders. Following this award, he holds 22,700 derivative securities directly.
Tonix Pharmaceuticals Holding Corp. reported that director Carolyn E. Taylor received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share and expire on May 12, 2036.
The award was granted under Tonix’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the May 12, 2026 grant date and the company’s 2027 Annual Meeting of Stockholders. Following this grant, Taylor holds stock options for 22,700 shares as reported in this filing.
Tonix Pharmaceuticals Holding Corp. director and Chief Executive Officer Seth Lederman reported an indirect open-market purchase of 5,000 shares of common stock on March 31, 2026 through an IRA account. The weighted average purchase price was about $12.62 per share, from trades between $12.5699 and $12.625.
Following this transaction, the IRA account holds 20,001 shares indirectly, while Lederman also holds 4,005 shares directly and 1 share indirectly through Lederman & Co., an entity for which he may be deemed a control person.
Tonix Pharmaceuticals Holding Corp. Chief Executive Officer Seth Lederman bought 15,000 shares of common stock in an open-market transaction at $14.89 per share through an IRA account.
After this purchase, he held 15,001 shares indirectly via the IRA, 4,005 shares directly, and 1 share indirectly through Lederman & Co., where he may be deemed a control person.
Tonix Pharmaceuticals Holding Corp. reported that Chief Operating Officer Jessica Edgar Morris received two grants of stock options. One grant covers 39,012 stock options and the other covers 39,011 stock options, both awarded at an exercise price of $0.00 per share.
According to the vesting terms, one-third of each option grant vests on the first anniversary of issuance, with the remaining portion vesting in equal monthly installments over the following 36 months. The options were granted under the company’s Amended and Restated 2020 Stock Incentive Plan.
SAENGER BRADLEY reported acquisition or exercise transactions in this Form 4 filing.
Tonix Pharmaceuticals Holding Corp. reported that Chief Financial Officer Bradley Saenger received two grants of stock options on February 24, 2026, covering 39,012 and 39,011 underlying shares. The options were issued under the company’s Amended and Restated 2020 Stock Incentive Plan.
According to the vesting terms, one-third of each option grant vests on the first anniversary of issuance, with the remaining portion vesting in equal monthly installments of 1/48 each month over the following 36 months. These awards increase the CFO’s directly held derivative securities in the company.
SULLIVAN GREGORY M reported acquisition or exercise transactions in this Form 4 filing.
Tonix Pharmaceuticals Holding Corp. Chief Medical Officer Gregory M. Sullivan reported receiving two grants of stock options covering 39,012 and 39,011 shares on February 24, 2026. One-third of each option grant vests on the first anniversary of issuance, with the remaining portion vesting monthly over the following 36 months. The options were granted under the company's Amended and Restated 2020 Stock Incentive Plan.
Fogarty Siobhan reported acquisition or exercise transactions in this Form 4 filing.
Tonix Pharmaceuticals Holding Corp. reported that Chief Technology Officer Siobhan Fogarty received two grants of stock options. One option covers 39,012 shares and the other covers 39,011 shares, both recorded as awards with no cash paid per option at grant.
According to the terms, one-third of each option vests on the first anniversary of issuance, and the remaining portion vests in equal monthly installments over the following 36 months. The options were granted under the company’s Amended and Restated 2020 Stock Incentive Plan, providing long-term, equity-based compensation tied to the company’s share performance.
Tonix Pharmaceuticals Holding Corp. reported that Chief Executive Officer Seth Lederman received two grants of stock options. Each grant is for stock options at an exercise price of $0.00 per share, dated February 24, 2026, and held directly by him.
One option grant covers 134,504 stock options and the other covers 134,503 stock options. According to the filing, one-third of each option vests on the first anniversary of issuance, with the remaining portion vesting in equal monthly installments over the following 36 months. The options were granted under the company’s Amended and Restated 2020 Stock Incentive Plan.